Aligos Therapeutics, Inc. Research and Development Expense
Aligos Therapeutics, Inc. (ALGS) reported Research and Development Expense of $24.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Aligos Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $24.05M, a 72.08% increase year-over-year.
- Aligos Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $23.35M, a 61.03% increase year-over-year.
- Aligos Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $17.04M, a 6.28% increase year-over-year.
- Aligos Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $23.94M, a 42.70% increase year-over-year.
- Aligos Therapeutics, Inc. research and development expense for fiscal 2025 was $69.45M, a 1.16% decline from fiscal 2024.
- Aligos Therapeutics, Inc. research and development expense for fiscal 2024 was $70.27M, a 3.79% decline from fiscal 2023.
- Aligos Therapeutics, Inc. research and development expense for fiscal 2023 was $73.04M, a 14.15% decline from fiscal 2022.
- Aligos Therapeutics, Inc. research and development expense for fiscal 2022 was $85.08M, a 18.32% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.05M 10-Q · filed 2026-08-06 | $47.40M 10-Q · filed 2026-08-06 | $64.44M derived: sum of 3 quarters · filed 2026-08-06 | $88.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $23.35M 10-Q · filed 2026-05-07 | $40.39M derived: sum of 2 quarters · filed 2026-05-07 | $64.33M derived: sum of 3 quarters · filed 2026-05-07 | $78.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $17.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $40.98M derived: sum of 2 quarters · filed 2026-03-05 | $54.95M derived: sum of 3 quarters · filed 2026-08-06 | $69.45M 10-K · filed 2026-03-05 |
| 2025-09-30 | $23.94M 10-Q · filed 2025-11-06 | $37.91M derived: sum of 2 quarters · filed 2026-08-06 | $52.41M 10-Q · filed 2025-11-06 | $68.45M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $13.98M 10-Q · filed 2026-08-06 | $28.48M 10-Q · filed 2026-08-06 | $44.51M derived: sum of 3 quarters · filed 2026-08-06 | $61.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $14.50M 10-Q · filed 2026-05-07 | $30.53M derived: sum of 2 quarters · filed 2026-05-07 | $47.31M derived: sum of 3 quarters · filed 2026-05-07 | $68.41M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $16.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $32.80M derived: sum of 2 quarters · filed 2026-03-05 | $53.90M derived: sum of 3 quarters · filed 2026-03-05 | $70.27M 10-K · filed 2026-03-05 |
| 2024-09-30 | $16.77M 10-Q · filed 2025-11-06 | $37.87M derived: sum of 2 quarters · filed 2025-11-06 | $54.24M 10-Q · filed 2025-11-06 | $76.50M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $21.10M 10-Q · filed 2025-08-06 | $37.46M 10-Q · filed 2025-08-06 | $59.72M derived: sum of 3 quarters · filed 2025-08-06 | $75.59M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $16.37M 10-Q · filed 2025-05-06 | $38.62M derived: sum of 2 quarters · filed 2025-05-06 | $54.49M derived: sum of 3 quarters · filed 2025-05-06 | $71.27M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $22.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $38.12M derived: sum of 2 quarters · filed 2025-03-10 | $54.91M derived: sum of 3 quarters · filed 2025-03-10 | $73.04M 10-K · filed 2025-03-10 |
| 2023-09-30 | $15.87M 10-Q · filed 2024-11-06 | $32.65M derived: sum of 2 quarters · filed 2024-11-06 | $50.78M 10-Q · filed 2024-11-06 | $69.88M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $16.78M 10-Q · filed 2024-08-06 | $34.92M 10-Q · filed 2024-08-06 | $54.02M derived: sum of 3 quarters · filed 2024-08-06 | $71.81M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $18.14M 10-Q · filed 2024-05-07 | $37.23M derived: sum of 2 quarters · filed 2024-05-07 | $55.03M derived: sum of 3 quarters · filed 2024-05-07 | $71.54M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $19.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $36.89M derived: sum of 2 quarters · filed 2024-03-12 | $53.40M derived: sum of 3 quarters · filed 2024-03-12 | $85.08M 10-K · filed 2024-03-12 |
| 2022-09-30 | $17.79M 10-Q · filed 2023-11-02 | $34.30M derived: sum of 2 quarters · filed 2023-11-02 | $65.98M 10-Q · filed 2023-11-02 | $94.58M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $16.51M 10-Q · filed 2023-08-03 | $48.19M 10-Q · filed 2023-08-03 | $76.78M derived: sum of 3 quarters · filed 2023-08-03 | $104.92M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $31.68M 10-Q · filed 2023-05-04 | $60.27M derived: sum of 2 quarters · filed 2023-05-04 | $88.41M derived: sum of 3 quarters · filed 2023-05-04 | $112.96M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $28.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $56.73M derived: sum of 2 quarters · filed 2023-03-09 | $81.28M derived: sum of 3 quarters · filed 2023-03-09 | $104.15M 10-K · filed 2023-03-09 |
| 2021-09-30 | $28.13M 10-Q · filed 2022-11-02 | $52.69M derived: sum of 2 quarters · filed 2022-11-02 | $75.56M 10-Q · filed 2022-11-02 | $103.64M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $24.55M 10-Q · filed 2022-08-04 | $47.42M 10-Q · filed 2022-08-04 | $75.50M derived: sum of 3 quarters · filed 2022-08-04 | $92.84M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $22.87M 10-Q · filed 2022-05-04 | $50.95M derived: sum of 2 quarters · filed 2022-05-04 | $68.28M derived: sum of 3 quarters · filed 2022-05-04 | $85.46M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $28.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $45.41M derived: sum of 2 quarters · filed 2022-03-10 | $62.59M derived: sum of 3 quarters · filed 2022-03-10 | $79.89M 10-K · filed 2022-03-10 |
| 2020-09-30 | $17.33M 10-Q · filed 2021-11-04 | $34.51M derived: sum of 2 quarters · filed 2021-11-04 | $51.81M 10-Q · filed 2021-11-04 | $66.78M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $17.18M 10-Q · filed 2021-08-05 | $34.48M 10-Q · filed 2021-08-05 | $49.45M derived: sum of 3 quarters · filed 2021-08-05 | $61.18M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $17.30M 10-Q · filed 2021-05-10 | $32.27M derived: sum of 2 quarters · filed 2021-05-10 | $44.00M derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | $14.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $26.70M derived: sum of 2 quarters · filed 2021-03-23 | $44.04M 10-K · filed 2021-03-23 | |
| 2019-09-30 | $11.73M 10-Q · filed 2020-11-25 | $29.07M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |